Solving COVID: December 2, 2020
The U.K. approves a COVID-19 vaccine, Moderna says its vaccine candidate prevents severe illness, and more
![A vaccine.](https://cdn.mos.cms.futurecdn.net/o5D7LbPhTT7LLNWFTRpngM-415-80.jpg)
- 1. U.K. approves Pfizer-BioNTech COVID-19 vaccine for widespread emergency use, starting next week
- 2. Moderna says its COVID-19 vaccine is 100 percent effective at preventing severe cases
- 3. FDA approves test designed to measure specific COVID-19 antibody levels
- 4. CDC advisory panel recommends long-term care residents, health-care workers receive vaccine first
- 5. Director of global pharma group anticipates as many as 10 COVID-19 vaccines by 2021
1. U.K. approves Pfizer-BioNTech COVID-19 vaccine for widespread emergency use, starting next week
Britain's medicine and health-care regulator, the MHRA, gave emergency approval Wednesday for the COVID-19 vaccine made by Pfizer and BioNTech, making the U.K. the first country to green-light the promising vaccine for mass rollout. Britain has already ordered 40 million doses of the vaccine, or enough to inoculate 20 million people, and the first doses should arrive in the coming days. "Help is on its way," Health Secretary Matt Hancock tweeted: "The NHS stands ready to start vaccinating early next week." Pfizer and Moderna have both reported a 95 percent effectiveness rate for their vaccines from large human clinical trials. The U.S. Food and Drug Administration is expected to grant such authorization for both vaccines in the next two or three weeks.
2. Moderna says its COVID-19 vaccine is 100 percent effective at preventing severe cases
All but 11 of the 196 Moderna COVID-19 vaccine trial participants who contracted the virus were in the placebo group, good for a 94 percent efficacy rate. But, perhaps even more crucially, none of the people who received the vaccine developed a severe infection, the company said. There were 30 severe cases — including one death — in the trial, but all of those occurred in the placebo group. Experts have previously highlighted the importance of companies separating out the worst cases in vaccine trials, arguing that a candidate's true efficacy should be determined by its ability to protect against severe infections. It appears Moderna has done just that.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
![https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg](https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516-320-80.jpg)
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The Associated Press The New York Times
3. FDA approves test designed to measure specific COVID-19 antibody levels
The Food and Drug Administration approved a "new generation" of COVID-19 antibody test designed to detect how well people are protected against subsequent infection. Most antibody tests are able to tell whether a person has contracted the virus or not, and some can estimate the level of neutralizing antibodies someone has, CNBC notes. But the newly-authorized COVID-SeroKlir developed by Kantaro BioSciences measures specific levels. The catch is that scientists aren't sure if high levels of antibodies guarantee COVID-19 immunity, so the test won't necessarily serve as proof that someone is protected against re-infection. What it will do, however, is allow researchers to gain a better understanding of the correlation between antibody levels and immunity, which will come in handy both for people who have been exposed to the virus already and for vaccine development.
4. CDC advisory panel recommends long-term care residents, health-care workers receive vaccine first
The Centers for Disease Control and Prevention will advise that health-care workers and long-term care facility residents receive COVID-19 vaccinations first, if and when Food and Drug Administration approval is granted. The decision was reached by the Advisory Committee on Immunization Practices, which is advising the CDC on vaccine distribution practices. As vaccine approval for emergency use becomes increasingly likely in the coming weeks, the panel voted 13-1 in favor of a motion elevating two groups to the front of the line. Health-care workers are frequently exposed to the virus and are essential to keeping hospitals running throughout the pandemic, while nursing homes have faced some of the deadliest COVID-19 outbreaks across the country.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
5. Director of global pharma group anticipates as many as 10 COVID-19 vaccines by 2021
Thomas Cueni, the director-general of the International Federation of Pharmaceutical Manufacturers and Associations, said that as many as 10 COVID-19 vaccines could be available by the middle of next year, as long as they are granted approval by regulatory agencies. Cueni noted that the vaccine developers that have already released info from late-stage trials — Pfizer and BioNTech, Moderna, and the University of Oxford and AstraZeneca — have all showed promising results (although the latter is amending its trial after confusing results), and he expects similar data from Johnson & Johnson, Novavax, Sanofi Pasteur, GSK, and Merck. "But all of them need to be submitted by rigorous scientific scrutiny by the regulators," he said.
Create an account with the same email registered to your subscription to unlock access.
-
Why the UK phone signal is so poor
Under The Radar Having trouble connecting? A lack of investment, planning rules and even your home could be to blame
By Elizabeth Carr-Ellis, The Week UK Published
-
Battleground states to watch in the 2024 election
In Depth These seven states could end up deciding who wins the White House this year
By Justin Klawans, The Week US Published
-
Leave the crowds behind at these 7 sensational hotels
The Week Recommends Traveling in September means more room to explore
By Catherine Garcia, The Week US Published
-
Deadly 'brain-eating' amoebas could be spreading thanks to climate change
Under the Radar Naegleria fowleri causes rare and lethal infection, but recent uptick in cases suggests it is thriving in warming waters
By Harriet Marsden, The Week UK Last updated
-
Hongchi Xiao: slapping therapy 'master' convicted of manslaughter
The Explainer Alternative therapy has amassed 'cult-like following' worldwide, but 'self-healing' practice led to deaths of two diabetics
By Harriet Marsden, The Week UK Published
-
India's toxic alcohol problem
Under the Radar Bootleggers add lethal methanol to illegal liquor to cheaply increase potency, leading to widespread casualties
By Harriet Marsden, The Week UK Published
-
In what countries is assisted dying legal or under review?
In the spotlight More countries are granting more people the right to die
By Devika Rao, The Week US Published
-
Nigeria's worsening rate of maternal mortality
Under the radar Economic crisis is making hospitals unaffordable, with women increasingly not receiving the care they need
By Harriet Marsden, The Week UK Published
-
Dengue hits the Americas hard and early
Speed Read Puerto Rico has declared an epidemic as dengue cases surge
By Peter Weber, The Week US Published
-
How happy is Finland really?
Today's Big Question Nordic nation tops global happiness survey for seventh year in a row with 'focus on contentment over joy'
By Harriet Marsden, The Week UK Published
-
How Tehran became the world's nose job capital
Under the radar Iranian doctors raise alarm over low costs, weak regulation and online influence of 'Western beauty standards'
By Harriet Marsden, The Week UK Published